Hansa Biopharma AB (publ) HNSBF
Set alert
3.29 USD 0.00 0.00%
At close · Oct 29
2.93 Day range 2.93
2.90 52-week range 4.58
- YTD
- +13.02%
- 1 year
- -28.19%
- Open
- 2.93
- Prev close
- 3.29
- Mkt cap
- 328.02M
- Vol
- 150
- Avg vol
- 93
- EPS
- -0.84
- P/E
- 0.00
More statistics
- Low
- 2.93
- High
- 2.93
2Y chart
Signals (20)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Sep 29, 2026 | 1 month ago |
| RSI: Oversold | Sep 29, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 19, 2026 | 2 months ago |
| SMA: Bullish | Jul 30, 2026 | 3 months ago |
| RSI: Overbought | Jul 30, 2026 | 3 months ago |
| MACD: Buy Signal | Dec 1, 2025 | 11 months ago |
| SMA: Bearish | Nov 6, 2025 | 11 months ago |
| SMA: Bearish | Nov 6, 2025 | 11 months ago |
| RSI: Oversold | Nov 6, 2025 | 11 months ago |
| MACD: Sell Signal | Oct 20, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 1, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 30, 2025 | 1 year ago |
| SMA: Bullish | Sep 10, 2025 | 1 year ago |
| SMA: Bullish | Sep 10, 2025 | 1 year ago |
| RSI: Overbought | Sep 10, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 6, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 17, 2025 | 1 year ago |
| RSI: Oversold | Jul 17, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 24, 2024 | 1 year ago |
News
- Hansa Biopharma announces positive Idefirix PAES results presented in the High-Impact Clinical Trials session at ASN Kidney Week
- Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Sees Large Increase in Short Interest
- Hansa Biopharma Partners with Cradle to Advance AI-Driven Protein Design and Engineering
- Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia
- Hansa Biopharma AB (publ) (HNSBF) Q2 2026 Earnings Call Transcript
- Hansa Biopharma participating in Wedbush PacGrow Renal Summit
- Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA
- Hansa Biopharma AB (publ) (HNSBF) Analyst/Investor Day Transcript
- Hansa Biopharma AB (publ) (HNSBF) Discusses Top Line Results from PAES Study on Imlifidase in Highly Sensitized Kidney Transplant Patients Transcript
- Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation
Your note
Sign in to keep a note on HNSBF — it syncs with the Stock Master app.